olivLaw · US equity research
Akso Health Group AHG
Services-Business Services, NEC · SIC 7389 · Vertical: Services-Business Services, NEC (SIC 7389)
Akso Health Group is a China-based company listed on NASDAQ that has moved from microlending and social e-commerce into medical device sales and online healthcare services. Net revenues were 13.8 million USD in fiscal 2026, and the net loss narrowed compared with the prior year, which makes the shift into healthcare worth following closely.
At the close of 04 Nov 2026, Akso Health Group (AHG) stock was 1.33 USD (+9.92% on the day), with market capitalisation 2.2 bn USD, P/E 133.0 on diluted EPS of 0.01 USD over the last 12 months, dividend yield 29.87%, beta 0.58, 52-week range 0.69–2.50 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 56.4
- strong (55–70)
- Bollinger (20, 2)
- 1.17 – 1.43
- in the upper half of the band · %B 0.62 · band width 20.1%
- SMA 50 / 200
- 1.04 / 1.51
- mixed trend
- MACD (12, 26, 9)
- 0.06 / 0.08
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +14.7% | −1.1% | +15.8 pp | — |
| 3 months | −8.9% | −0.5% | −8.5 pp | — |
| 6 months | −35.1% | +4.4% | −39.5 pp | — |
| Year to date | −18.9% | +12.3% | −31.2 pp | — |
| 1 year | −16.4% | +13.5% | −29.9 pp | +0.9% |
| 3 years | +15.7% | +76.4% | −60.8 pp | +3.9% |
| 5 years | −69.3% | +63.7% | −133.0 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 80 percentile of its own 5-quarter history (min 7.4, median 24.8, max 228.0; quarters with earnings only).
Fiscal years
| Fiscal year | ⚠ 2019 | 2020 | 2021 | ⚠ 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7 m | 6.9 m | 1.8 m | 6.0 m | 13.2 m | 2.4 m | 14.8 m | 13.8 m |
| Revenue YoY | — | +87.1% | −74.6% | — | +119.7% | −81.7% | +512.1% | −6.4% |
| Net income | 5.5 m | -71.2 m | -34.8 m | -16.9 m | -1.4 m | -9.5 m | -135.0 m | -18.7 m |
| Net income YoY | — | −1,386.9% | unavailable | — | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | 0.10 | -1.46 | -0.71 | -0.28 | -0.02 | 0.07 | 0.16 | 0.01 |
| Diluted EPS YoY | — | −1,560.0% | unavailable | — | unavailable | unavailable | +128.6% | −93.8% |
| net % | 149.7% | -1,029.7% | -1,984.5% | -280.9% | -10.3% | -391.8% | -913.4% | -135.0% |
| Free cash flow | -1.7 m | -58.5 m | unavailable | -8.6 m | unavailable | unavailable | 1.0 m | -12.8 m |
The series breaks before 2019, 2022: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2026 · 31 Mar 2026
- Cash
- 170.6 k USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 180.9 m USD
- Total assets
- 189.6 m USD
- Debt / equity
- unavailable
- Current ratio
- 21.77x
- ROE
- -9.8%
- ROA
- -9.2%
- FCF margin
- -92.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.8 m | 6.0 m | 13.2 m | 2.4 m | 14.8 m | 13.8 m | SEC (XBRL)· 23 Jul 2026verified |
| Cost of revenue | 544.6 k | 5.4 m | 11.9 m | 2.3 m | 15.1 m | 13.8 m | SEC (XBRL)· 23 Jul 2026verified |
| Gross profit | 1.8 m | 605.1 k | 1.3 m | 122.1 k | -281.5 k | -11.3 k | SEC (XBRL)· 23 Jul 2026verified |
| Research & development | 441.4 k | 421.2 k | — | — | — | — | SEC (XBRL)· 29 Dec 2022verified |
| SG&A | — | — | — | 8.6 m | 3.6 m | 4.0 m | SEC (XBRL)· 23 Jul 2026verified |
| Operating income | -4.2 m | -3.3 m | -14.3 m | -8.6 m | -166.3 m | -20.7 m | SEC (XBRL)· 23 Jul 2026verified |
| Depreciation & amortisation | 15.2 k | 18.4 k | — | — | 2.1 m | 2.4 m | SEC (XBRL)· 23 Jul 2026verified |
| EBITDA | -4.2 m ≈ | -3.2 m ≈ | — | — | -164.2 m ≈ | -18.3 m ≈ | SEC (XBRL)· 23 Jul 2026derived |
| Interest expense | 2.2 m | 804.1 k | — | — | — | — | SEC (XBRL)· 14 Jul 2023verified |
| Pre-tax income | -4.3 m | -4.0 m | -13.1 m | -9.1 m | -166.3 m | -20.7 m | SEC (XBRL)· 23 Jul 2026verified |
| Income tax | 483.0 k | 92.8 k | 17.5 k | 25.0 k | -30.8 m | -2.0 m | SEC (XBRL)· 23 Jul 2026verified |
| Net income | -34.8 m | -16.9 m | -1.4 m | -9.5 m | -135.0 m | -18.7 m | SEC (XBRL)· 23 Jul 2026verified |
| Diluted EPS | -0.71 | -0.28 | -0.02 | 0.07 | 0.16 | 0.01 | SEC (XBRL)· 23 Jul 2026verified |
| Weighted average diluted shares | 48.8 m | 59.6 m | 68.6 m | 141.5 m | 855.3 m | 2.2 bn | SEC (XBRL)· 23 Jul 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 15.1 m | 18.4 m | 7.9 m | 85.2 m | 176.2 m | 170.6 k | SEC (XBRL)· 23 Jul 2026verified |
| Receivables | — | — | 7.7 m | — | 954.2 k | 1.3 m | SEC (XBRL)· 23 Jul 2026verified |
| Inventories | — | 7.8 m | 1.7 m | 191.2 k | 190.2 k | 200.1 k | SEC (XBRL)· 23 Jul 2026verified |
| Current assets | 30.1 m | 62.8 m | 20.5 m | 142.0 m | 196.1 m | 189.5 m | SEC (XBRL)· 23 Jul 2026verified |
| Property, plant & equipment, net | 66.9 k | 55.4 k | — | — | 16.1 k | 12.0 k | SEC (XBRL)· 23 Jul 2026verified |
| Goodwill | — | — | — | 52.1 m | 10.8 m | — | SEC (XBRL)· 14 Aug 2025verified |
| Intangibles (excl. goodwill) | — | — | — | — | 7.9 m | 58.3 k | SEC (XBRL)· 23 Jul 2026verified |
| Total assets | 31.7 m | 62.8 m | 20.5 m | 142.0 m | 215.0 m | 189.6 m | SEC (XBRL)· 23 Jul 2026verified |
| Current liabilities | 14.4 m | 50.5 m | 11.6 m | 3.6 m | 13.8 m | 8.7 m | SEC (XBRL)· 23 Jul 2026verified |
| Total liabilities | 14.4 m | 50.5 m | 11.6 m | 3.6 m | 15.8 m | 8.7 m | SEC (XBRL)· 23 Jul 2026verified |
| Equity | 17.3 m | 12.3 m | 8.8 m | 138.4 m | 199.2 m | 180.9 m | SEC (XBRL)· 23 Jul 2026verified |
| Shares outstanding at year end | 48.9 m | 68.6 m | 68.6 m | 437.2 m | 1.7 bn | — | SEC (XBRL)· 14 Aug 2025verified |
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 10.1 m | -8.6 m | -3.3 m | 1.4 m | 1.2 m | -12.8 m | SEC (XBRL)· 23 Jul 2026verified |
| Capex | — | 4.9 k | — | — | 154.5 k | 1.6 k | SEC (XBRL)· 23 Jul 2026verified |
| Free cash flow | — | -8.6 m ≈ | — | — | 1.0 m ≈ | -12.8 m ≈ | SEC (XBRL)· 23 Jul 2026derived |
| Investing cash flow | -662 | -20.0 m | 18.5 m | -54.7 m | -105.9 m | -163.5 m | SEC (XBRL)· 23 Jul 2026verified |
| Financing cash flow | -9.0 m | 34.8 m | -27.5 m | 131.7 m | 195.9 m | 350.0 k | SEC (XBRL)· 23 Jul 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 37.5% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 2.2 bn USD
Key indicators
Coverage and freshness
Score by group
38% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.17 – 7.02 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E0.17 – 0.38 (Mid 0.26)27 companies used · median multiple 25.7x · quartiles 17.3x – 37.8xACN, AMTM, BR, CART, CPAY, DLO, EBAY, EXLS, FICO, FIS, FLYW, GRAB, HQY, IMXI, LQDT, LYFT, MA, MELI, MSCI, OPRX, PYPL, QNST, RBA, RELY, TNET, UBER, WU
- Dividend discount (DDM)5.22 – 7.02 (Mid 5.99)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -135.0% | 5 (vs peers) | 17% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 1.6% | 13 (on a fixed band) | 22% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 21.8x | 100 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | 133.0x | 0 (vs peers) | 28% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -0.6% | 0 (on a fixed band) | 22% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial13/100 · 1/2 factors with a value
- Quality· partial5/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation0/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Akso Health Group (AHG). Latest full fiscal year: 2026; data up to 2026-03-31.
Figures computed from the financial statements: revenue 13.8 m USD in 2026; YoY growth -6.4%; net margin -135.0%; ROE -9.8%.
The estimated value range is 2.70–3.70 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 3.12 USD, the price of 1.33 USD leaves a potential of 134.8% (value / price − 1) and a margin of safety of 57.4% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 21.8x
- The price is below the estimated value range
What contradicts it
- Net margin: -135.0%
- Revenue CAGR 3Y: 1.6%
- P/E (TTM): 133.0x
- FCF yield: -0.6%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Business Services, NEC (SIC 7389) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| UBERUber Technologies, Inc. | 142.7 bn | 41.3 | 12.4% | 6.1% | +18.3% | −20% / +24% |
| MELIMercadoLibre, Inc. | 88.2 bn | 47.3 | 27.5% | 5.3% | +39.1% | −16% / +7% |
| EBAYeBay Inc. | 54.9 bn | 27.2 | 46.6% | 16.9% | +7.9% | +51% / +205% |
| PYPLPayPal Holdings, Inc. | 50.0 bn | 11.5 | 23.8% | 13.8% | +4.3% | −4% / +4% |
| MSCIMsci Inc. | 48.2 bn | 35.7 | — | 40.3% | +9.7% | +20% / +29% |
| FISVFiserv, Inc. | 33.0 bn | — | -17.0% | -18.9% | +3.6% | +1% / −52% |
| CPAYCorpay, Inc | 27.5 bn | 25.4 | 30.5% | 22.7% | +13.9% | +42% / +74% |
| GPNGlobal Payments Inc. | 25.4 bn | — | -4.1% | -9.1% | −0.4% | +27% / −17% |
| BRBroadridge Financial Solutions, Inc. | 21.4 bn | 20.9 | 40.2% | 13.9% | +8.5% | −17% / −2% |
| RBARB Global, Inc | 17.6 bn | 39.9 | 8.8% | 10.0% | +7.2% | −3% / +49% |
| FISFidelity National Information Services, Inc. | 15.3 bn | 4.4 | 23.0% | 26.8% | +5.4% | −55% / −49% |
| FICOFair Isaac Corp | 15.1 bn | 20.3 | — | 34.1% | +15.9% | −61% / −36% |
| CARTMaplebear Inc. | 13.7 bn | 32.4 | 17.1% | 12.0% | +10.8% | +41% / +145% |
| HQYHealthequity, Inc. | 9.0 bn | 39.4 | 11.4% | 17.4% | +9.5% | +3% / +62% |
| LYFTLyft, Inc. | 7.1 bn | 2.7 | 152.6% | 42.3% | +9.2% | −11% / +60% |
| EXLSExlservice Holdings, Inc. | 6.5 bn | 25.7 | 27.7% | 11.1% | +13.6% | +9% / +52% |
| RELYRemitly Global, Inc. | 5.8 bn | 16.4 | 35.9% | 19.1% | +29.4% | +100% / +26% |
| AMTMAmentum Holdings, Inc. | 5.4 bn | 26.7 | 4.5% | 1.4% | +71.6% | −22% / unavailable |
| DLODLocal Limited | 4.1 bn | 21.4 | 37.2% | 18.0% | +46.6% | +3% / −19% |
| TNETTrinet Group, Inc. | 3.1 bn | 18.1 | 141.6% | 3.6% | −0.9% | +14% / −42% |
| FLYWFlywire Corporation | 2.7 bn | 36.3 | 9.1% | 10.3% | +26.6% | +56% / −6% |
| TICTIC Solutions, Inc. | 2.3 bn | — | -7.1% | -5.6% | unavailable | +10% / unavailable |
| AHGAkso Health Group | 2.2 bn | 133.0 | -9.8% | -135.0% | −6.4% | −16% / +16% |
| WUThe Western Union Company | 2.1 bn | 6.3 | 36.8% | 8.3% | −3.8% | −25% / −43% |
| LQDTLiquidity Services, Inc | 1.5 bn | 45.8 | 15.0% | 6.8% | +31.2% | +56% / +144% |
1- and 3-year price returns: for AHG from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Akso Health Group is a China-based company listed on NASDAQ that has moved from microlending and social e-commerce into medical device sales and online healthcare services. Net revenues were 13.8 million USD in fiscal 2026, and the net loss narrowed compared with the prior year, which makes the shift into healthcare worth following closely.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Dependence on insurance clientshigh
A small number of insurance companies generate most revenue. Losing or reducing the budget of one of them could seriously affect the financial position 1.
- Dependence on traffic suppliershigh
If relations with digital traffic suppliers deteriorate, the company could deliver fewer leads to insurers 1.
- Personal data securityhigh
The company processes sensitive client data, and a security breach could lead to liability and loss of trust 1.
- Infrastructure riskmedium
Services depend on China's internet network and on data centres located in the country, with no business interruption insurance 1.
- Asset impairmentmedium
The company recorded significant impairments of goodwill and intangible assets, which shows the risk that acquisitions may not reach their value 1.
Investment thesis
What would need to be true (bull case)
- If the integration of Tianjin Wangyi Cloud succeeds and synergy with physical hospitals is confirmed, the company could build a more stable revenue stream in digital health 1.
- The net loss narrowed compared with the prior year, which could point to better cost discipline 1.
- The company's experience reorienting its business in recent years could facilitate further healthcare acquisitions if conditions are favourable 1.
What would break the thesis
- Revenue is highly concentrated and fell compared with the prior year, which could indicate a business that is still fragile 1.
- Large impairments of goodwill and intangible assets could suggest earlier acquisitions were overvalued 1.
- Chinese regulation can change operating conditions for online hospitals and pharmacies quickly, which could affect the company's plans 1.
What to watch
- Development of car insurance promotion revenue and client countnext 10-K
- New acquisitions of online hospitals or pharmacy chains2027
- Stability of relations with digital traffic suppliersnext 10-K
- Results of integrating Tianjin Wangyi CloudQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The company was founded as Hexindai Inc. and operated a P2P lending platform until it disposed of it in December 2020, then became Xiaobai Maimai Inc. and, from December 2021, Akso Health Group. According to the 20-F 1, it now focuses on selling medical devices and providing marketing promotion services. Net revenues were 13.8 million USD in fiscal 2026 1.
Medical device sales run through Qingdao Akso in China, which distributes devices such as defibrillators and anesthesia laryngoscopes to distributors and end users. The subsidiary Akso Online MediTech previously sold COVID-19 rapid tests in the US, but these sales ceased at the start of 2023 1.
Since April 2024, through Tianjin Wangyi Cloud, the company has provided promotion services to car insurance broker agencies and earns commissions based on recommendations made. The company now holds 100% of Tianjin Wangyi Cloud, which operates an online hospital and sells medicines online 1.
Segments
Marketing promotion services
In fiscal 2026, marketing promotion service revenue was 13,835,063 USD, effectively all of revenue 1. The company depends on a small number of insurance company clients and on digital traffic suppliers that bring potential car insurance buyers 1.
Medical devices
Medical device sales were 415,020 USD in fiscal 2025 and nil in fiscal 2026, according to the revenue table in the report 1. The segment has effectively stopped, leaving the company without revenue from this line.
Online healthcare and pharmacies
The company intends to acquire online hospitals and independent pharmacy chains in China, but says such acquisitions will be made at judicious timing and subject to favorable market and regulatory conditions 1. Results in this segment will depend on integrating the acquisitions already made 1.
Market context
The company operates in healthcare services and digital health in China, a market with intense competition among online hospitals and pharmacies. The report also describes the car insurance marketing market, where the company sells its referral services 1. In that market, revenues depend on the marketing budgets of a few large clients 1.
The report describes the e-commerce market for medical products and supplements, as well as telemedicine services, as expanding in China, without quantifying the market size 1. The company says it wants to benefit from the synergy between online medicine and physical hospitals 1.
Trends
- Integration of online medicine with physical hospitalstailwind
The company argues that synergy between online medicine and physical hospitals could create value if integration succeeds 1.
- Regulation of digital healthheadwind
Acquisitions of online hospitals and pharmacies depend on regulatory conditions in China, which could slow the company's plans 1.
- Dependence on insurance clientsheadwind
Concentration among insurance company clients makes revenue sensitive to changes in their budgets 1.
- Demand for online medical servicesmixed
If demand for online consultations keeps growing, Tianjin Wangyi Cloud could become a more stable source of revenue 1.
Competitive position
The 20-F does not name direct competitors, but competition in online healthcare services and independent pharmacies in China is described as intense 1. The company competes with other digital traffic and marketing providers in car insurance promotion 1.
In car insurance promotion the company relies on external traffic suppliers, and losing one could reduce the number of leads delivered 1. Competition in this niche could affect the company's margins 1.
- Digital traffic suppliers for car insurance
External traffic and digital marketing providers on which the company depends to reach potential buyers 1.
- Online hospitals and health platforms in China
Operators of online consultations and medicine sales that compete with the company's services 1.
- Pharmacy chains in China
Companies operating pharmacy chains that the company intends to acquire or compete with 1.
- Medical device suppliers
Distributors and manufacturers of medical equipment with which the company competes in the Chinese market 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Annual report (foreign issuer)23 Jul 2026
- Current report (foreign issuer)13 May 2026
- Current report (foreign issuer)23 Mar 2026
- Current report (foreign issuer)10 Feb 2026
- Annual report (foreign issuer)14 Aug 2025
- Current report (foreign issuer)01 May 2025
- Current report (foreign issuer)28 Mar 2025
- Current report (foreign issuer)08 Nov 2024
- Annual report (foreign issuer)30 Jul 2024
- Current report (foreign issuer)02 May 2024
Sources
- [1] Form 20-F, fiscal year ended 2026-03-31 · SEC / Akso Health Group · 23 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.